An analysis of the ADVANCE study shows that the treatment effect of perindopril-indapamide in patients with diabetes is independent of SBP, DBP or 10-year ASCVD risk at baseline.
Comprehensive joint and stratified analyses on sitting, physical activity and all-cause or CV mortality risk evaluated the effects of replacing sitting with various physical activity patterns on mortality risk. With poll.
Bleeding on probing, increased probing pocket depth, caries or fillings in childhood were associated with increased IMT 27 years later, independent of cumulative exposure to CV risk factors.
In a study that aimed to address the healthy donor effect, women who had frequently donated blood in the first 10 years of their donation career, showed fewer CV events than those less often donating.
A prospective, accelerometer-based study shows that total sedentary time and the pattern in which it accumulates (long bouts vs interrupted) are positively associated with the risk of CVD in older women.
Cardio Diabetes Masterclass Dubai Prof. John Deanfield discusses two new drug classes that benefit T2DM patients in terms of CV risk, with different modes of action indicating different potential for clinical implications.
Several incorrect beliefs exist about cholesterol lowering. Prof. Ray and prof. Montalescot discuss the importance of physician and patient education to improve their knowledge.
Prof. Deanfield sheds light on the relation between T2DM and CVD, and how studies evaluating novel classes of antidiabetic drugs have evolved over time, from revealing safety signals to demonstrating CV benefit.
New insights into lipid management have emerged since 2016. Prof. Ray discusses with prof. Mach in which respects the guidelines should be changed.
A meta-analysis including recent trials and data of over 157.000 individuals shows no benefit of aspirin for primary CV prevention, and a higher risk of major bleeding and intracranial hemorrhage
PCSK9: Outcomes and trials in clinical perspective PCSK9 inhibitors should be mainly considered for the highest risk categories on maximally tolerated statin plus ezetimibe. Prof. Kees Hovingh discusses how to identify these high risk patients.
CME accredited course focussed on how new developments with antidiabetic drugs will impact the management of CVD. Member registration (free) is needed to enroll in this course